Pharmaceuticals

FDA approves Tris Pharma’s Onyda XR, a once-daily extended-release oral suspension for the treatment of ADHD

bexib
By bexib 0 Min Read

The approval of Onyda XR makes it the first non-stimulant liquid medication for attention-deficit hyperactivity disorder to be marketed in the United States.

You Might Also Like

Efcitra demonstrates non-inferiority to insulin glargine and degludec in type 2 diabetes

FDA Grants Fast Track Designation to Clarity Pharmaceuticals’ Novel Treatment for PSMA-Positive Prostate Cancer Lesions

Pharma Pulse 5/23/24: GoodRx offers discounts on fertility treatments and more, medical services immigrant children need most

Johnson & Johnson MedTech Introduces Velys Active Robotic-Assisted System for Planning and Instrumentation in Spinal Fusion Surgery

Parkinson’s UK awards ICL £100,000 to develop mini drug for Parkinson’s disease

Share This Article
Previous Article Is the MEV monster under Bitcoin’s bed?
Next Article Vast lithium resources discovered in Pennsylvania could help ensure U.S. energy independence
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Toyota Financial Services Three ways to utilize next -generation AI
Banking
HSBC shuts down cross-border payments app
Banking
Fiserv appoints PNC Lions chairman to replace Bisignano
Banking
2025 Blueprint: American-Made Infrastructure
Manufacturing